Evaluation of the Protective Efficacy of Reshaped Human Monoclonal Antibody RSHZ19 against Respiratory Syncytial Virus in Cotton Rats

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Pediatric Research

• Publication date

  1995-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1203/00006450-199510000-00012PMID 8559607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin.

  1994cited by this paper
• Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection

  1993cited by this paper
• Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus–Infected Mice with Respiratory Syncytial Virus–Specific Immune Serum

  1993cited by this paper
• Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.

  1993cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993cited by this paper
• Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

  1992cited by this paper
• Respiratory syncytial virus: babies and antibodies.

  1992cited by this paper
• Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

  1992cited by this paper
• Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.

  1992influential reference
• Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo

  1991cited by this paper
• Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections

  1990cited by this paper
• Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

  1989cited by this paper
• Reshaping human antibodies for therapy

  1988cited by this paper
• Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes

  1988cited by this paper
• Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats

  1987cited by this paper
• Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

  1987cited by this paper
• Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

  1986cited by this paper
• Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

  1985influential reference
• Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model.

  1985cited by this paper
• Two distinct subtypes of human respiratory syncytial virus.

  1985cited by this paper
• Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

  1981cited by this paper

• Preclinical animal models to evaluate therapeutic antiviral antibodies.

  2024cites this paper
• Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens.

  2022cites this paper
• Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?

  2021cites this paper
• A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

  2019cites this paper
• Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

  2011cites this paper
• RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy

  2009cites this paper
• Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Viruses

  2009cites this paper
• Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein.

  2008cites this paper
• Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

  2007cites this paper
• A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo

  2007cites this paper
• The growth and potential of human antiviral monoclonal antibody therapeutics

  2007cites this paper
• The Cotton Rat (Sigmodon hispidus) Is a Permissive Small Animal Model of Human Metapneumovirus Infection, Pathogenesis, and Protective Immunity

  2005cites this paper
• Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.

  2005cites this paper
• Development of a cotton rat-human metapneumovirus (hMPV) model for identifying and evaluating potential hMPV antivirals and vaccines.

  2005cites this paper
• Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays.

  2004cites this paper
• Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro.

  2003cites this paper
• Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection.

  2003cites this paper
• A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus

  2000cites this paper
• Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4‐specific monoclonal antibodies: CD4+ T‐cell depletion is not required

  2000cites this paper
• Active and passive immunisation against respiratory syncytial virus

  1999cites this paper
• SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection

  1999cites this paper
• Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease

  1999cites this paper
• Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment

  1999cites this paper
• Chemotherapy of respiratory viruses: prospects and challenges.

  1999cites this paper
• A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

  1999cites this paper
• Intranasal Antibody Prophylaxis for Protection against Viral Disease

  1999cites this paper
• Respiratory syncytial virus antiviral agents

  1999cites this paper
• Novel Therapeutics from Modern Biotechnology

  1999cites this paper
• Prevention and treatment of respiratory syncytial virus infections.

  1999cites this paper
• A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo

  1998cites this paper
• -Prevention of respiratory syncytial virus infection-.

  1998cites this paper
• The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.

  1998cites this paper
• Respiratory syncytial virus (RSV) disease and prospects for its control.

  1998cites this paper
• CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats.

  1998cites this paper
• Prévention de l'infection par le virus respiratoire syncytial

  1998cites this paper
• Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syncytial virus.

  1998cites this paper
• Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients.

  1997cites this paper
• Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein.

  1997cites this paper
• Reproductive toxicology. Theobromine.

  1997cites this paper
• The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

  1996cites this paper
• Efficacy of RD3-0028 Aerosol Treatment against Respiratory Syncytial Virus Infection in Immunosuppressed Mice

  1996cites this paper
• Treatment of Respiratory Syncytial Virus Bronchiolitis: Hope and Despair

  1996cites this paper